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Abstract
Objective The heterodimeric IL-12 family member cytokines including, IL-12, IL-23, IL-27, and IL-35 and have multiple 
roles in regulating innate and adaptive immunity with crucial functions in inflammatory disorders such as psoriasis. Chain 
pairing promiscuity is a feature of the IL-12 family. Recently, based on murine data, a new family member, IL-39, was 
proposed, consisting of IL23p19 (shared with IL-23) and EBI3 (shared with IL-27 and IL-35). IL-39 has subsequently been 
implicated in experimental murine lupus. Given the success of IL-23p19 therapeutic targeting in diseases including psoriasis, 
it is of great interest to confirm the presence of IL-39 in man. Human IL-39 is yet to be either detected or expressed, which 
has halted research in this area.
Methods Using a disulphide-linked human chimera protein composing of IL-23p19 and EBI3 human chains, we stimulated 
human leukocytes, and analysed cytokine secretion and STAT3 phosphorylation.
Results and Conclusion We report that this cytokine shows no activity in human cells. IL-39 chimera protein failed to induce 
either IL-6, IL-8, TNF, or IL-17A from leukocytes or STAT3 phosphorylation and thus, remains a ‘theoretical cytokine’ in 
humans.
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Introduction
Cytokines are usually grouped into families, which are based 
on amino acid homology and structural characteristics. The 
IL-12 family members are unique, in that they form heter-
odimers comprised of α-subunits and β-subunits [1]. IL-12 
was the first member of this family to be discovered, and 
along with other family members, IL-23 and IL-27, they are 
predominantly secreted by activated antigen presenting cells 
[1]. IL-12 has a central role in polarization and promotion of 
type I immune responses which are characterized by prefer-
ential release of interferon gamma [1]. IL-23 induces IL-17 
from a range of conventional and non-conventional lympho-
cytes (the IL-23/IL-17 axis) [2]. While IL-27 shows immune 
activating activity, the overall (albeit context specific) effect 
of IL-27 seems to be regulatory in a range of disease models 
[3]. As recently published [4], the property of IL-27 to act on 
co-inhibitory receptor regulation seems important. The most 
recent ‘fully recognized’ member of the family in humans 
is IL-35. IL-35 is secreted by Tregs and also activated B 
cells, and has immunosuppressive functions [5, 6]. IL-12 
family cytokines have an essential function in a wide range 
of physiologic responses in particular pathogen defense and 
protection of the intestinal mucosa and elicit functions via 
phosphorylation of members of the signal transducer and 
activator of transcription (STAT) family of transcription fac-
tors [1]. As evidenced by the success of IL-12 family-related 
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biologics (ustekinumab, guselkumab, and risankizumab) but 
also by described pathologies for loss of function mutations 
of IL-12 cytokine receptors such as Mendelian susceptibil-
ity to mycobacterial diseases (MSMD) [7], IL-12 family 
cytokines are heavily implicated in pathogen defense but 
also inflammatory disease. IL-23 has been shown to be a 
key orchestrator of the psoriatic disease spectrum and thera-
peutic targeting has proved successful in this disease [2, 8].
Recently, a new IL-12 family member was discovered 
in mice, IL-39. The IL-39 heterodimer consists of IL-
23p19 (shared with IL-23) and EBI3 (shared with IL-27 
and IL-35). Murine IL-39 is secreted by activated B cells, 
and activates neutrophils and was shown to mediate inflam-
mation in lupus like mice [9, 10]. Ustekinumab, originally 
thought to impact on IL-12p40, is now thought to show its 
disease modifying activity by IL-23 (IL-12p40 + IL-23p19) 
inhibition. Recent data from several clinical trials as well 
as real-life clinical observations strongly suggest that IL-
23p19 blockers such as risankizumab and guselkumab are 
superior to ustekinumab in psoriasis [11]. Of course, any 
efficacy difference between IL-12p40 blockers and IL-23p19 
blockers could also be attributed to blocking of the IL-23p19 
chain of IL-39. Thus, confirmation of IL-39 in humans is 
of great interest. Human IL-39 has not yet been detected 
or expressed, meaning that research into the area is slow. A 
recent report studying IL-12 family chain pairings in human 
cells detected all other IL-12 family pairings, but failed to 
detect a EBI3 + IL-23p19 combination, raising doubts over 
the existence of this cytokine in man [12]. We, thus, aimed 
to study the effect of a disulfide-linked IL-39 chimera pro-
tein on human cells.
Methods
Leukocyte stimulation and ELISA
Blood from healthy volunteers was collect in EDTA tubes. 
Red blood cells were lysed with red cell lysis buffer and leu-
kocytes were subsequently plated out at a concentration of 
5 × 105 per well in RPMI 1640 +10% FCS. Cells were stimu-
lated with LPS (50 ng/ml) (Sigma) or IL-39 (10–100 ng/ml) 
(R&D Systems) for 48 h. Secretion of TNF, IL-6, and IL-8 
into the supernatant was tested by ELISA. For IL-17 ELISA 
measurement, as a positive control 5 × 105 cells were stimu-
lated with plate bound anti CD3 (10 µg/ml) and anti-CD28 
(10 µg/ml) (both Thermofisher) for 48 h. All ELISA kits 
were purchased from Thermofisher and carried out accord-
ing to the manufacturer’s instructions. Analysis was per-
formed using GraphPad Prism software (GraphPad Software 
Inc, La Jolla, CA, USA). Error bars represent the standard 
error of the mean (SEM).
Western blot and flow cytometry
Cells were stimulated as before with IL-39 (100 ng/ml) or 
IL-6 (20 ng/ml) (Peprotech). Cells were lysed with CelLytic 
M lysis buffer (Sigma-Aldrich), containing protease inhibi-
tor cocktail (Roche Applied Bioscience, Rotkreuz, Swit-
zerland) and phosphatase inhibitor (Thermofisher). Protein 
concentration was determined by Bradford Assay, and 30 μg 
of total protein was separated on any kDa mini protean gel 
(Bio-Rad). Proteins were blotted onto 0.2 μm PVDF trans-
blot pack (Bio-Rad). Membranes were incubated with either 
mouse anti-human GAPDH (Abcam), STAT3 (Abcam), or 
phospho-STAT3 (Cell Signaling), in 5% BSA overnight at 4 
°C according to the manufacturers’ instructions. Membranes 
were subsequently incubated with secondary antibody, HRP 
conjugated donkey anti-mouse (Santa Cruz) according to 
the manufacturer’s instructions for 1 h at room tempera-
ture. For flow cytometry analysis, cells were stimulated as 
before. Using IntraPrep Permeabilizaton kit (Beckman Coul-
ter) according to the manufacturer’s instructions, cells were 
stained with mouse anti-human phospho-STAT3 or isotype 
control (PE-Cyanine7, eBioscience, both 1:50). Cells were 
analysed using the LSRII (BD Biosciences) and a FlowJo 
software (Tree Star Software, San Carlos, California, USA).
Results
IL‑39 does not induce cytokine secretion 
from human leukocytes
Previous research from a murine model suggests that IL-39 
primarily acts upon neutrophils, so we decided to stimu-
late whole leukocytes (typically 60–70% neutrophils) with 
IL-39 chimera protein (10, 50, and 100 ng/ml) for 48 h. No 
significant induction in IL-6, IL-8, or TNF was achieved in 
comparison to untreated cells. As expected LPS stimulation 
resulted in a statistically significant increase in IL-6, IL-8, 
and TNF. IL-39 was also found to have no additive effect on 
LPS induced cytokine production (Fig. 1a, c and d).
As IL-23 drives IL-17 secretion from T cells, we also 
investigated whether IL-39 may share this ability. Leuko-
cytes stimulated with anti-CD3/C28 secreted IL-17 (mean 
217 pg/ml), but IL-39 had no effect on IL-17, either alone 
or additive (Fig. 1b).
IL‑39 does not induce STAT3 phosphorylation
The previous publications on mouse cells suggest that IL-39 
signals through STAT3 [9, 13]. When human leukocytes 
were stimulated with IL-39, no increase in phospho-STAT3 
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was detected (Fig. 1e, f). As expected, a positive control with 
IL-6 stimulation increased phospho STAT3.
Discussion
IL-39 is cytokine implicated in murine lupus models [9]. 
As IL-39 shares the common p19 chain with IL-23, hypo-
thetically, p19 blockers could be blocking the activity of 
this cytokine in man. Whilst our findings do not disprove 
the existence of IL-39 in humans, they suggest that it should 
remain theoretical for the time being. The case for the exist-
ence of IL-39 in humans based on probability is high. While 
not all human cytokines exist in mouse, all other confirmed 
members of the IL-12 family have, thus, far proved to exist 
in both mice and man; however, data seem stronger for 
murine p40 homodimer, while it is still debated to play a 
meaningful pathophysiological role in humans [3, 14]. In 
our study, an IL-39 chimera protein, consisting of EBI3 and 
IL-23p19 chains linked by a disulphide bond, was unable 
to stimulate human leukocytes. Furthermore, IL-39 also 
showed no signaling potential via STAT3 phosphorylation.
Whilst the chimera nature of the protein may not mirror 
the true structure of the heterodimer, the same protein does 
have reported activity in mouse splenocytes (R&D systems). 
The corresponding receptor complex for IL-39 (IL-23R/
gp130) has also been shown to be active on murine cells 
and results in STAT3 activation; however, this has not been 
confirmed in humans [13]. However, in mice, it has been 
reported that EBI3 shows activity as a monomer to signal 
and stimulate cells, meaning that it is plausible that the EBI3 
subunit of the heterodimer could be solely responsible for 
functional effects seen. It is known, however, in human that 
EBI3 is not secreted as a monomer [15]. A recent report into 
combinatorial potential of IL-12 chain pairs in human cells 
was able to detect all other IL-12 family cytokines (IL-12, 
IL-23, IL-27, and IL-35) but not IL-39, which, along with 
our study, raises questions over the existence of this cytokine 
in man [12]. In conclusion, our study fails to confirm a func-
tional response to IL-39 in man, suggesting that this chain 
pairing may only play a role in murine immune responses.
Fig. 1  IL-39 shows no activity in human leukocytes. Human leuko-
cytes were stimulated with IL-39 and or LPS, and secreted concentra-
tion of TNF, IL-6, and IL-8 was determined by ELISA (a, c and d). 
Leukocytes were stimulated with IL-39, with and without anti-CD3/
CD28, and secreted concentration of IL-17 was determined by ELISA 
(b) (n = 4). Leukocytes were stimulated with IL-39 (100  ng/ml) or 
IL-6 (20  ng/ml) for 15  min and subsequently probed for phospho 
STAT3 or GAPDH using western blot method (e). Cells were stimu-
lated as before, and subsequently intracellularly stained for phospho-
STAT3, and signal measured using flow cytometry (f). a–d Signifi-
cance reported between treatments and unstimulated (unless stated). 
Paired t-test
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